CORE

🇺🇦   make metadata, not war

    2 research outputs found

    A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance.

    Author
    Publication venue
    'American Society of Clinical Oncology (ASCO)'
    Publication date
    Field of study
    No full text
    Crossref
    corecore